Not bad placement at .031 compared to yesterdays close of...

Not bad placement at .031 compared to yesterdays close of .032


VISIOMED GROUP LTD ANNOUNCES PLACEMENT TO
FUND COMMERCIALISATION OF FUNHALER

April 28th 2005, Australia: Visiomed Group Ltd (ASX code: VSG) announced that the company is raising
approximately $620,000 by way of an excluded offer to qualified investors in the United Kingdom and
Australia.
The funds raised will supplement existing working capital and will be applied in the commercialisation of the
Funhaler® including initial sales in Australia, and the set up for large scale manufacturing to supply the major
USA and European markets.
The Company’s Australian distributors, Cottman Australia will launch the Funhaler® in the June quarter of
2005 and have committed to the take up and distribution of 20,000 Funhaler®units in the first year. The CEO
of Visiomed Group, Dr William Dolphin, said this was an encouraging first move as Australia represented
approximately 1% of the world market. The company will be displaying the Funhaler® at the upcoming May
2005 meeting of the American Thoracic Society in San Diego, California. The ATS meeting is the largest
gathering of Pulmonary and Critical Care specialists in the world.
The funds will be raised through a placement of 20 million shares at 3.1 cents per share. The offer includes
one attaching free March 2008 option exercisable at 12 cents per share for every four shares placed (a total
of 5 million options).
The Company expects to complete the placement within two weeks.
About Visiomed Group Ltd
Visiomed (www.visiomed.com.au) develops and commercialises innovative medical devices. Apart from the
Funhaler®, Visiomed also has the exclusive world wide licences for computer-based smart systems for the
imaging and diagnosis of diseases other than dermatological conditions. The company is utilising its
intellectual property to develop the microEYE™ imaging system as an aid in the screening and diagnosis of
eye diseases such as cataract, glaucoma, trachoma, macular degeneration and diabetic retinopathy.
About the Funhaler®
The Funhaler® is a children’s incentive spacer for the effective delivery of asthma drugs, developed in
Australia. It incorporates incentive modules that respond to inhalation and was designed to encourage
children to take their asthma medication. The Funhaler® is covered by international patents issued and
pending.
Clinical studies involving the Funhaler® are currently under way with support of a $1 million grant from the
US National Institutes of Health. The Funhaler® is protected in multiple countries by broad coverage patents
issued and pending (Reference: USPTO: 6,578,571). This coverage already extends to protection of a wide
range of alternative incentive toy modules in the Funhaler circuit.
-